KROS: Keros Therapeutics, Inc. Common Stock Company Profile & Statistics

About

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.

Info & Links

CEO

Jasbir Seehra

Headquarters

1050 WALTHAM STREET, SUITE 302
LEXINGTON, MA 02421, UNITED STATES

Auditor

Deloitte & Touche LLP

Share holders

Employees

169

Keros Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

558.62M

Enterprise Value

-161.92M

Enterprise Value/EBITDA(ttm)

17.96

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

686.32

Price to Book(mrq)

0.78

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-27890.94%

Profit Margin(ttm)

-34351.85%

Return on Equity(ttm)

-41.74%

Return on Invested Capital(ttm)

-8.38%

Return on Assets(ttm)

-38.42%

Income Statement

Revenue(ttm)

214.71M

Revenue Per Share(ttm)

5.29

Gross Profit(ttm)

214.71M

EBITDA(ttm)³

-9.01M

Net Income Available to Common(ttm)

4.21M

Diluted EPS(ttm)

-5.21

Share Statistics

Beta (5Y Monthly)

1.39

52-Week Change

-72.53%

S&P 500 52-Week Change

9.20%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

40.62M

Dividend Yield

0.00%

Float⁴

31.23M

% Held by Insiders

22.90%

% Held by Institutions

71.56%

Balance Sheet

Total Cash(mrq)

720.54M

Total Cash Per Share(mrq)

17.74

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

19.29%

Quick Ratio(mrq)

19.03%

Book Value Per Share(mrq)

17.97

Cash Flow

Operating Cash Flow Per Share(ytd)

3.93

Free Cash Flow(ytd)

160.61M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

KROS

Keros Therapeutics, Inc. Common Stock

Keros Therapeutics, Inc. Common Stock Profile